(Q45751095)

15 December 2017

title

Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective (English)

1 reference

15 December 2017

1 reference

1 reference

G K Lau

1

1 reference

15 December 2017

W F Carman

2

1 reference

15 December 2017

S A Locarnini

3

1 reference

15 December 2017

K Okuda

4

1 reference

15 December 2017

Z M Lu

5

1 reference

15 December 2017

R Williams

6

1 reference

15 December 2017

S K Lam

7

1 reference

15 December 2017

publication date

1 January 1999

1 reference

15 December 2017

Journal of Gastroenterology and Hepatology

published in

1 reference

15 December 2017

volume

14

1 reference

15 December 2017

issue

1

1 reference

15 December 2017

page(s)

3-12

1 reference

15 December 2017

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Natural history and control of perinatally acquired hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Review: Present and future directions in the treatment of chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Immunologic and molecular basis of viral persistence. The hepatitis B virus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Recovery from chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Current therapeutic trends in therapy for chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Efficacy of interferon alfa-2b with or without prednisone withdrawal in the treatment of chronic viral hepatitis B. A prospective double-blind Belgian-Dutch study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Gene inoculation generates immune responses against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Viral dynamics in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.1999.01812.X

10.1046/J.1440-1746.1999.01812.X

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017